Skip to content
Clinical Trials – home
PortugalBack to Portugal

Clinical trials in Amadora – page 7

673 clinical trials in Amadora, Portugal across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Amadora at a glance
673
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

673 trials in Amadora

Open in trial search

Long‑Term Safety and Tolerability of Oral Fesoterodine in Adults with Hallucinations and Delusions Due to Alzheimer’s Disease Psychosis

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Betovumeline
  • Sponsor:Maplight Therapeutics Inc.

VMX-C001 in Patients Taking Factor Xa Inhibitors Who Need Urgent Surgery or an Invasive Procedure With High Bleeding Risk

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:VMX-C001
  • Sponsor:VarmX B.V.

Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Nipocalimab
  • Sponsor:Janssen Cilag International

Neoplasm

Recruiting

EIK1005 Alone and with Pembrolizumab for Advanced Solid Tumors in Patients with MSI-H or dMMR Tumors

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:EIK1005 sodium
  • Sponsor:Eikon Therapeutics Inc.

Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Obrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Boehringer Ingelheim Espana S.A.

Asthma

Recruiting

GB-0895 for Severe Uncontrolled Asthma in Adults and Adolescents

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:GB-0895
  • Sponsor:Generate Biomedicines Inc.

A Study of BI 764532, Atezolizumab, Carboplatin, and Etoposide in Patients With Extensive-Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Boehringer Ingelheim Espana S.A.

A study to evaluate the safety and effectiveness of IKT-001 compared to a placebo in adults with pulmonary arterial hypertension.

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:IKT-001PRO
  • Sponsor:Inhibikase Therapeutics Inc.

Homocystinuria

Recruiting

A study to evaluate the safety and effectiveness of pegtibatinase in patients aged 12 to 65 years with classical homocystinuria.

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pegtibatinase
  • Sponsor:Travere Therapeutics Inc.

Comparing sotorasib and pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Amgen Inc.

Study of the efficacy and safety of depigmented polymerized grass pollen extracts for patients with allergic rhinitis and controlled asthma.

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dactylis Glomerata Pollen Extract
  • Sponsor:LETI Pharma S.L.U.

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Amadora

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on breast cancer treatments, including studies for HER2-positive and triple-negative variants. Research evaluates new therapeutic approaches for ovarian cancer and non-small cell lung cancer.

  • Chemotherapy-free treatments for HER2+ breast cancer
  • Advanced therapies for platinum-resistant ovarian cancer
  • Combination immunotherapy approaches

Multiple studies exploring targeted therapies and immunotherapy combinations to improve patient outcomes.

02 Autoimmune Conditions

Clinical research targeting systemic lupus erythematosus and related conditions. Studies evaluate novel treatments for scleroderma-related lung disease and inflammatory conditions.

  • Long-term safety studies for lupus treatments
  • Interstitial lung disease interventions
  • Novel therapeutic approaches for autoimmune disorders

Focus on developing safer and more effective treatments for chronic autoimmune conditions.

03 Cardiovascular and Metabolic Disorders

Research examining treatments for Type 2 diabetes with cardiovascular complications. Studies investigating new approaches for stroke prevention and vascular health.

  • Diabetes cardiovascular outcomes
  • Post-stroke treatment strategies
  • Vascular disease management

Comprehensive evaluation of therapeutic interventions for complex cardiometabolic conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.